CompletedEUCTR 2016-003529-41
CANGLIA: Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophrenia
This historical record does not confirm current site availability.
Historical research recordNetherlands
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with schizophrenia. Other eligibility criteria applied.
- Listed locations
- Netherlands
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- University Medical Center Utrecht
- Sponsor type
- Hospital / academic medical center
- Study type
- Biological
- Intervention type
- Biological
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Netherlands
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2016-003529-41
- Official title
Show the full official title
CANGLIA: Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Netherlands
Registry details
Historical country statuses
- Netherlands — Completed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University Medical Center Utrecht, a hospital or academic medical center.
Who was this study for?
This study was for people with schizophrenia. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Pa...
A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder.